What tirzepatide is, and what sets it apart from other incretins

Tirzepatide is a fatty-acid-modified peptide that activates two receptors at once: GIP and GLP-1. Earlier compounds in this family acted only on the second. That is its entire novelty, and it was literally the question its foundational paper asked: whether adding GIP activity contributed anything beyond what a selective GLP-1 receptor agonist already delivered [1].

What has been published, and in how many people

Unlike most compounds in this catalogue, here the data come from clinical trials in humans, not from animal models. They were run under medical supervision, with pharmaceutical-grade product, inside approved and registered protocols.

• Body weight. The SURMOUNT-1 trial, randomised and placebo-controlled in 2,539 adults with obesity or overweight and without diabetes, described a mean weight reduction of 20.9% at week 72 in the highest-dose group, against 3.1% on placebo. In that group, 57% lost at least 20% of their body weight, against 3% on placebo [2].
• What happens on stopping. SURMOUNT-4 is a withdrawal trial: 670 participants lost a mean 20.9% over a 36-week open-label lead-in, then were assigned either to continue or to switch to placebo. Over the following 52 weeks, those who continued lost a further 5.5% and those who stopped regained 14.0% [3]. It is the least-cited figure and the one that says most about the nature of the effect.
• Obstructive sleep apnoea. In two phase 3 trials in adults with moderate-to-severe apnoea and obesity, the authors measured a fall in the apnoea-hypopnoea index of 25.3 events per hour at week 52, against 5.3 on placebo, among participants not using positive airway pressure [4].

Across the three trials, the most frequent adverse events were gastrointestinal and mostly mild to moderate, concentrated in the escalation period.

The distinction almost nobody makes

The molecule is approved. This vial is not that medicine.

Tirzepatide holds a marketing authorisation in the European Union [5], for specific indications, with its patient leaflet, its summary of product characteristics, pharmaceutical batch control, pharmacovigilance and a prescription. A research reagent has none of that. It is manufactured and analysed to serve in a laboratory, not to be administered to a person, and it is not part of the pharmaceutical supply chain.

That excellent clinical trials exist on this molecule says nothing about what is inside a vial that did not come from a pharmacy. They are two different things, and only the second is sold here, for in vitro research.

This page describes published literature. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional. If what you are looking for is a treatment, the route is your doctor.

What to look at when comparing suppliers

• HPLC purity for the specific batch, with a certificate you can read before buying.
• Identity confirmation by mass spectrometry, which matters especially in this family: several analogues have similar molecular weights, and a purity certificate does not tell you which one you have.
• A real cold chain, with refrigerated shipping and a transit time that does not leave the vial sitting for a week in a warm warehouse.